← Back to Clinical Trials
Recruiting NCT06385223

NCT06385223 A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06385223
Status Recruiting
Phase
Sponsor Institute of Mental Health, Singapore
Condition Depression
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2024-07-01
Primary Completion 2026-07-01

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Beam F3 targeted accelerated iTBSIndividualized connectome-guided accelerated iTBS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2024-07-01 with a primary completion date of 2026-07-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Investigators propose to carry out a randomized, double-blind trial to compare the clinical efficacy of an individualized connectome-guided accelerated iTBS vs an anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients and outpatients who had been referred for TMS for the treatment of depression.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 21 years. 2. DSM-5 diagnosis of current Major Depressive Episode. 3. Montgomery-Asberg Depression Rating Scale score of 20 or more. 4. Inadequate response to an adequate trial (4 weeks) of at least one antidepressant medication. 5. Able to give informed consent. Exclusion Criteria: 1. DSM-5 psychotic disorder 2. Drug or alcohol abuse or dependence (preceding 3 months). 3. Rapid clinical response required, e.g., high suicide risk. 4. Significant neurological disorder, which may pose increased risks with TMS, e.g., epilepsy. 5. Metal in the cranium, skull defects, pacemaker, cochlear implant, medication pump or other electronic device. 6. Pregnancy. 7. Unsuitable for MRI.

Contact & Investigator

Central Contact

Phern Chern Tor, MBBS

✉ phern_chern_tor@imh.com.sg

📞 63892000

Frequently Asked Questions

Who can join the NCT06385223 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06385223 currently recruiting?

Yes, NCT06385223 is actively recruiting participants. Contact the research team at phern_chern_tor@imh.com.sg for enrollment information.

Where is the NCT06385223 trial being conducted?

This trial is being conducted at Singapore, Singapore.

Who is sponsoring the NCT06385223 clinical trial?

NCT06385223 is sponsored by Institute of Mental Health, Singapore. The trial plans to enroll 70 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology